Skip to Main Content

Trending

October 3, 2022
Population Health
Article / Publication

Source: Population Health Management

Programmatic integrated approaches have been used successfully and cost-effectively to manage various chronic conditions. The incorporation of rtCGM in similar integrated approaches to diabetes management presents an opportunity to improve quality outcomes and reduce costs on a population level. This publication details the evidence to suggest it may be time to support broader adoption to incorporate the use of rtCGM.

Learn More
Share:
September 15, 2022
CGM Technology and Digital Health
CE Activities

CME INFORMATION

Release Date: 9/15/2022
Expiration Date: 9/15/2023

TARGET AUDIENCE
This activity is intended for primary care physicians and internal medicine physicians.

LEARNING OBJECTIVES
Upon completion of this activity, participants will:

  • Have increased knowledge regarding the Data supporting use of rtCGM in practice
  • Have greater competence related to Implementing practical strategies for
    using rtCGM in practice

Learn More

Share:
July 15, 2022
Clinical Outcomes
Conference Updates

Recap of real-time continuous glucose monitoring (rtCGM) abstracts from the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) – where innovation in diabetes medicines and treatments, cutting-edge technologies, and the latest research is presented. These abstracts are pertinent to managed care and payer decision makers and help characterize the value of rtCGM in improving clinical outcomes, decreasing avoidable healthcare utilization, and decreasing the burden of diabetes care management.

Learn More
Share:
May 19, 2022
Coverage and Benefit Design
Video

The American Diabetes Association (ADA) Standards of Medical Care represent the latest evidence-based recommendations for guiding clinical practice. According to the most recent edition of these guidelines, Level A evidence from the MOBILE study supports the use of real time continuous glucose monitoring (rtCGM) in patients with insulin-treated type 2 diabetes (T2D) regardless of regimen. The findings from the MOBILE study likewise demonstrate the value of rtCGM across typically underserved demographics of patients impacted by social determinants of health (SDOH). Taking the ADA recommendations into consideration, payers are formulating coverage policies that facilitate appropriate access to rtCGM, improved outcomes in T2D, and proven per-member-per-month (PMPM) cost savings. 

Share:
  • 1-0 of 0 results